Ro Sparks

Phase 2Small molecule

AAspargo Labs, Inc

Ro Sparks is one of 36 small molecule programs targeting Erectile Dysfunction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erectile DysfunctionActive, not recruiting

Erectile DysfunctionPhase 2

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Erectile Dysfunction

#DrugCompanyPhaseTrials

Levitra

Bayer

Phase 3

24 2

Zocor

OOrganon and Co

Phase 3

1 3

LCZ696

Novartis

Phase 3

1 4

Botulinum Toxin a

GSK

Phase 3

1 5

Myrbetriq

Astellas

Phase 2

2 6

Platelet Rich Plasma

ZZagazig University

Phase 3

3 7

Fluvastatin XL

Novartis

Phase 3

1 8

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 3

1 9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 10

TPN171H

VVigonvita Life Sciences

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Erectile Dysfunction1 trial

Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunction

Not yet recruiting·AAspargo Labs, Inc·Phase 2·NCT07231185·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ro Sparks. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ro Sparks compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ro Sparks. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aspargo Labs, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAspargo Labs, Inc

Ro Sparks

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Erectile Dysfunction1 trial

References

Drug Info

Quick Facts

Related News